<DOC>
	<DOCNO>NCT01525225</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics Saxagliptin , 5-hydroxy Saxagliptin , Metformin pediatric subject Type 2 diabetes mellitus ( T2DM ) follow oral administration Saxagliptin Metformin XR fix dose combination tablet co-administration Saxagliptin Glucophage® ( Metformin ) IR tablet</brief_summary>
	<brief_title>Study Saxagliptin , 5-Hydroxy Saxagliptin , Metformin Concentrations/Levels Pediatric Subjects With T2DM</brief_title>
	<detailed_description>The primary purpose ass pharmacokinetics Saxagliptin , 5-hydroxy Saxagliptin , Metformin pediatric subject age 10 17 year T2DM follow oral administration Saxagliptin Metformin XR fix dose combination tablet co-administration Saxagliptin Glucophage® ( Metformin ) IR tablet</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Clinical diagnosis T2DM Male female subject age 1017 Body weight ≥50 kg Glycosylated hemoglobin ( HbA1c ) 6.5 10 % Fasting plasma glucose ( FPG ) &gt; 240 mg/dL screen Abnormal renal function Active liver disease and/or significant abnormal liver function</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>